Nonsteroidal antiinflammatory drugs and reproduction

American Journal of Obstetrics and Gynecology

Volumn 169, Issue 5, 1993, Pages 1255-1265

  Dawood, M Yusoff ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

dysmenorrhea; Nonsteroidal antiinflammatory drugs; prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; FLUFENAMIC ACID; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; RITODRINE; SUPROFEN; TOLFENAMIC ACID;

DIARRHEA; FEMALE; HUMAN; META ANALYSIS; NAUSEA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; GENITAL DISEASES, FEMALE; HUMAN; POLYHYDRAMNIOS; PREGNANCY; PREGNANCY COMPLICATIONS; REPRODUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0027133092     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(93)90292-Q     Document Type: Article

References (110)

1. Inhibition of prostaglandin biosynthesis as a mechanism of action for aspirin-like drugs
2. Aspirin selectively inhibits prostaglandin production in human platelets
3. Indomethacin and aspirin abolish prostaglandin release from the spleen
4. Inhibition of prostaglandin biosynthesis
5. Inhibitors of prostaglandin, prostacyclin and thromboxane synthesis
6. Nonsteroidal anti-inflammatory aspects
7. Quantitative aspects of prostaglandin synthesis in man
8. Pharmacokinetic von indomethacin bei Schwangeren, Kreibenden, and deren Neugeborenen
9. Overall approach to the management of dysmenorrhea
10. Tissue selectivity and variability of effects of acetaminophen on arachidonic acid metabolism
11. Dysmenorrhea and prostaglandins pharmacological and therapeutic considerations
12. Salicylate-induced gastrointestinal bleeding: comparison between soluble buffered, enteric-coated and intravenous administration
13. Anti-secretory, cytoprotective and diarrheogenic properties of prostaglandins
14. Release of prostaglandins by IUCD
15. Prostaglandin-mediated action of IUDs. II. F-prostaglandins (PGF) in the uterine horn of pregnant rats and hamsters with intrauterine devices
16. Prostaglandin-mediated action of intrauterine devices: F-prostaglandins in the uterine horns of pregnant rabbits with unilateral intrauterine devices
17. Prostaglandin mediated luteolytic effect of an intrauterine device in sheep
18. Prostaglandins in the human endometrium: gas chromatographic mass spectrometric quantitation before and after IUD insertion
19. Prostaglandin E and F concentrations in human endometrium after insertion of intrauterine contraceptive device
20. Reduction by mefenamic acid of increased blood loss associated with intrauterine contraception
21. Reduction by naproxen of excessive menstrual bleeding in women when using intrauterine devices
22. Role of prostaglandins in IUD-associated uterine bleeding -effect of a prostaglandin synthetase inhibitor (ibuprofen)
23. The action of anti-inflammatory drugs on the fertility of female rats with intrauterine contraceptive devices
24. Hormones, prostaglandins, and dysmenorrhea
25. Choosing the correct therapy for dysmenorrhea
26. Etiology and treatment of dysmenorrhea
27. Dysmenorrhea
28. Dysmenorrhea
29. New concepts in dysmenorrhea
30. Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid
31. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy
32. Prostaglandins in primary dysmenorrhea comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives
33. The treatment of dysmenorrhea with naproxen sodium: a report of two independent double-blind trials
34. Prostaglandins, indomethacin, and dysmenorrhea
35. Studies in the involvement of prostaglandins in uterine symptomatology and pathology
36. Indomethacin and tolfenamic acid in primary dysmenorrhea
37. Trial of prostaglandin-synthetase inhibitors in primary dysmenorrhea
38. Endogenous prostaglandins in dysmenorrhea and the effect of prostaglandin synthetase inhibitors (PGSI) on uterine contractility
39. Simultaneous objective and subjective evaluation of meclofenamate sodium in the treatment of primary dysmenorrhea
40. Effects of naproxen sodium on menstrual prostaglandins and primary dysmenorrhea
41. Oxaprozin: a once-daily nonsteroidal antiinflammatory drug
42. A role for prostacyclin (PGI2) in excessive menstrual bleeding
43. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding
44. Human menstruation and eicosanoids
45. Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors
46. The use of the prostaglandin synthetase inhibitor mefenamic acid in the treatment of menorrhagia
47. Efficacy of mefenamic acid in patients with a complaint of menorrhagia
48. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid
49. Primary and myoma-associated menorrhagia: Role of prostaglandins and effect of ibuprofen
50. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia
51. The morphologic characteristics of menstrual hemostasis in patients with unexplained menorrhagia
52. Surgical induction of endometriosis in the rabbit: effects on fertility and concentrations of peritoneal fluid prostaglandins
53. Peritoneal fluid thromboxane B2 and 6-keto-prostaglandin Fla in endometriosis
54. Cul-de-sac fluid in women with endometriosis: fluid volume and prostanoid concentration during the proliferative phase of the cycle - days 8 to 12
55. Peritoneal fluid prostaglandins and prostanoids in women with endometriosis, chronic pelvic inflammatory disease, and pelvic pain
56. The prostanoid content in peritoneal fluid and plasma of women with endometriosis
57. Prostaglandin F in human endometriotic tissue
58. Prostaglandin biosynthesis inhibitors and endometriosis
59. Naproxen sodium in dysmenorrhea secondary to endometriosis
60. Premenstrual tension syndrome
61. Prostaglandins and central nervous system
62. Possible significance of renal prostaglandins for renin release and blood pressure control
63. The treatment of premenstrual symptoms with mefenamic acid
64. The effect of prostaglandin synthesis inhibition by indometh-acin on ovulation and ovum maturation in the in vitro perfused rabbit ovary
65. Inhibition of superovulation in immature female rats by the antiserum to cyclooxygenase
66. Effect of prostaglandin F2a on oviduct contractility in marmoset monkeys
67. Prostaglandins and the contractile function of the human oviductal ampulla
68. Prostaglandins in the human fallopian tube
69. Oxyphenbutazone, antiinflammatory agent in the prevention of peritoneal adhesions
70. Prevention of postoperative peritoneal adhesions with ibuprofen
71. Failure of a nonsteroidal anti-inflammatory agent (ibuprofen) to inhibit peritoneal adhesion reformation after lysis
72. Ibuprofen in the prevention of experimentally induced postoperative adhesion
73. The use of ibuprofen and dexamethasone in the prevention of postoperative adhesion formation
74. Prevention of post-operative adhesions in rabbits with ibuprofen, a nonsteroidal anti-inflammatory agent
75. Adhesion formation and uterine tube healing in the rabbit: a controlled study of the effects of ibuprofen and flurbiprofen
76. Inhibition of hatching of mouse blastocyst in vitro by various prostaglandin antagonists
77. The suppression of inflammatory edema at the nidation site by sodium salicylate and nitrogen mustard in the rat
78. Prostaglandin(s) as inductive factor of decidualization in the rat uterus
79. Suppression of concentration of endometrial prostaglandin in early intra-uter-ine and ectopic pregnancy in women
80. Reduced umbilical and placental vascular prostaglandin in severe pre-ec-lampsia
81. Reduced prostacyclin production in preeclampsia
82. Prostacyclin and pre-eclampsia
83. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production
84. A comparison of the pulmonary, renal, and hepatic extractions of PGI2 and PGE2-PGI2 a potential circulating hormone
85. Aspirin differentially affects thromboxane and prostacylin production by trophoblast and villous core compartment of human placental villi
86. Effect of low-dose aspirin on vascular refractoriness in angiotensin-sensitive primigravid women
87. 2 to prostacyclin in relatively high risk pregnancies
88. Low dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension
89. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease
90. Prevention of preeclampsia: low-dose aspirin in nulliparous women: a double-blind, placebo-controlled trial [Abstract 1]
91. Low-dose aspirin to prevent preeclampsia
92. The inhibition of premature labor with indomethacin
93. Further study of the inhibition of preterm labor by indomethacin.. II. Double-blind study
94. Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study
95. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor
96. A study of indomethacin combined with ritodrine in threatened preterm labor
97. Treatment of premature labor contractions with combined ritodrine and indomethacin
98. Possible association between maternal indomethacin and primary pulmonary hypertension of the newborn
99. Safety and efficacy of long-term tocolysis with indomethacin
100. Premature labor and indomethacin
101. Effect on neonate of maternal treatment with indomethacin
102. The effects of indomethacin and a ß-sympathomimet-ic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized, double-blind study
103. Fetal and neonatal effects of indomethacin used as a tocolytic agent
104. Neonatal outcome after indomethacin treatment for preterm labor
105. Further study of the inhibition of premature labor by indomethacin
106. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety
107. Influence of short-term indomethacin therapy on fetal urine output
108. Indomethacin-induced oligohydramnios
109. Treatment of polyhydramnios with prostaglandin synthetase inhibitor (indomethacin)